불면증 약물 치료 시장 : 세계 시장 예측(2026-2032년)

The Insomnia Pharmacological Treatment Market is projected to grow by USD 5.01 billion at a CAGR of 5.96% by 2032.

Insomnia pharmacological treatment is evolving as clinicians, payers, and regulators balance the need for effective sleep initiation and sleep maintenance therapies with safety, next-day functioning, dependence risk, and long-term patient outcomes. The treatment landscape includes prescription hypnotics, benzodiazepine receptor agonists, melatonin receptor agonists, orexin receptor antagonists, sedating antidepressants used in selected cases, and regionally available agents supported by local regulatory pathways. Clinical guidance continues to emphasize accurate diagnosis, assessment of comorbid psychiatric and medical conditions, medication review, and the use of cognitive behavioral therapy for insomnia as a foundational intervention, with pharmacotherapy considered when symptoms are clinically significant, persistent, or inadequately controlled. Demand for evidence-based insomnia medication is reinforced by the high burden of sleep disorders, aging populations, shift work, digital lifestyle disruption, and the increasing recognition that untreated insomnia is associated with impaired quality of life, workplace productivity loss, accident risk, and greater healthcare utilization. SEO-relevant themes shaping executive priorities include insomnia drugs, sleep disorder treatment, prescription sleep aids, orexin receptor antagonists, chronic insomnia management, pharmacological sleep therapy, hypnotic medications, and patient-centered sleep medicine.

Transformative Shifts in the Insomnia Treatment Landscape

The insomnia pharmacological treatment landscape is undergoing transformative shifts driven by safer mechanism-based therapies, tighter prescribing expectations, and a stronger focus on individualized care. Traditional sedative-hypnotic prescribing is being reassessed due to concerns regarding tolerance, dependence, falls, cognitive effects, respiratory comorbidity, and next-day psychomotor impairment, particularly among older adults and patients with polypharmacy. At the same time, orexin pathway modulation has expanded clinical interest because it targets wakefulness regulation rather than broad central nervous system depression, supporting a differentiated approach to chronic insomnia therapy. Regulatory agencies and clinical societies increasingly encourage careful benefit-risk evaluation, short-duration use where appropriate, patient counseling, and monitoring for complex sleep behaviors and residual sedation. Digital therapeutics, telehealth-based sleep assessment, wearable sleep data, and pharmacy-led medication management are also changing treatment access and adherence monitoring. These shifts are moving the sector from symptom suppression toward precision sleep care, where pharmacological treatment is integrated with behavioral intervention, comorbidity management, and real-world safety surveillance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence insomnia pharmacological treatment through improved screening, clinical decision support, medication safety analytics, and real-world evidence generation. AI-enabled tools can analyze electronic health records, prescription histories, wearable-derived sleep patterns, and patient-reported outcomes to help identify insomnia phenotypes, detect contraindications, flag drug-drug interactions, and support appropriate therapy selection. In research settings, machine learning can accelerate signal detection in pharmacovigilance databases, identify predictors of treatment response, and support trial design by improving patient stratification and endpoint measurement. AI is also enhancing remote monitoring by connecting digital sleep diaries, actigraphy, and adherence data, enabling clinicians to refine treatment plans more quickly. However, adoption must be governed by clinical validation, transparency, privacy protection, bias mitigation, and alignment with prescribing standards. The cumulative impact of artificial intelligence is not the replacement of clinical judgment, but the strengthening of safer, more personalized, and evidence-driven insomnia medication management.

Key Regional Insights Across Global Insomnia Treatment

In Asia-Pacific, insomnia pharmacological treatment is shaped by large urban populations, high work intensity, aging demographics in Japan, South Korea, China, and Australia, and growing awareness of sleep disorders across primary care and specialty channels. Regulatory and reimbursement pathways differ widely, creating variation in access to newer hypnotic classes and continued use of established therapies. North America demonstrates strong clinical adoption of guideline-informed insomnia management, broad availability of prescription sleep medications, and heightened scrutiny of controlled substances, medication safety, and older-adult prescribing. In Latin America, access patterns are influenced by public and private healthcare fragmentation, specialist availability, and the need for affordable sleep disorder treatment in countries with rising mental health and chronic disease burdens. Europe is characterized by structured pharmacovigilance, national prescribing guidance, and emphasis on nonpharmacological first-line care, while still maintaining demand for targeted pharmacotherapy in persistent insomnia. The Middle East is seeing increasing recognition of sleep disorders alongside lifestyle changes, metabolic disease prevalence, and expanding private healthcare infrastructure. Across Africa, insomnia treatment access remains uneven, with opportunities tied to primary care strengthening, mental health integration, essential medicine availability, and better diagnosis of sleep disorders in populations affected by stress, urbanization, and comorbid disease.

Key Group Insights for Insomnia Pharmacological Treatment

ASEAN markets reflect diverse healthcare maturity, with insomnia pharmacological treatment adoption influenced by urbanization, workplace stress, private pharmacy access, and growing investment in mental health services across major economies. The GCC is marked by expanding specialty care, high digital health readiness, and increasing attention to sleep disorders associated with obesity, diabetes, shift work, and lifestyle-related risk factors. Within the European Union, harmonized medicine safety expectations coexist with country-specific reimbursement and prescribing practices, supporting careful use of insomnia drugs and ongoing preference for behavioral treatment integration. BRICS countries present substantial clinical need due to large populations, rising chronic disease burden, and expanding healthcare access, while also showing variability in regulatory capacity, affordability, and availability of newer sleep medications. G7 countries generally show higher clinical guideline penetration, stronger pharmacovigilance infrastructure, and broader availability of advanced therapies, making medication optimization, deprescribing, and real-world outcomes central priorities. NATO member countries overlap significantly with advanced healthcare systems in North America and Europe, where insomnia treatment strategies are increasingly linked to military readiness, veteran health, stress-related sleep disturbance, and safe prescribing in populations with mental health comorbidities.

Key Country Insights in Insomnia Pharmacological Treatment

The United States has a highly developed insomnia treatment environment with broad prescription availability, strong direct clinical awareness, and ongoing concern regarding sedative safety, controlled-substance use, and treatment of insomnia comorbid with anxiety, depression, pain, and sleep apnea. Canada emphasizes evidence-based prescribing, public health awareness, and cautious medication use, particularly among older adults. Mexico and Brazil show growing demand for sleep disorder treatment as urban stress, mental health burden, and private healthcare access expand, though affordability and specialist distribution remain important considerations. In the United Kingdom, insomnia management is strongly influenced by national clinical guidance, primary care gatekeeping, and emphasis on behavioral interventions before or alongside pharmacotherapy. Germany, France, Italy, and Spain combine mature regulatory oversight with country-specific prescribing traditions and reimbursement approaches, supporting careful selection of hypnotic medications for chronic insomnia and short-term sleep disturbance. Russia presents demand linked to stress-related sleep disorders and neurological care pathways, with local access dynamics shaping pharmacological choices. China and India carry large unmet clinical needs due to population scale, urbanization, aging, and increasing recognition of sleep health, while access, diagnosis rates, and affordability vary across regions. Japan has significant relevance due to its aging population, high sleep complaint prevalence, and strong attention to medication safety in older adults. Australia reflects guideline-driven care, increasing use of digital health support, and careful monitoring of sedative-hypnotic prescribing. South Korea combines advanced healthcare access, high work-related stress exposure, and growing sleep medicine awareness, supporting demand for clinically differentiated insomnia therapies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that demonstrates clinically meaningful improvements in sleep onset, sleep maintenance, next-day functioning, safety, and patient-reported quality of life. Development strategies should focus on differentiated mechanisms, lower abuse potential, favorable older-adult safety profiles, and compatibility with comorbidity-driven prescribing. Stakeholders should strengthen real-world evidence programs, pharmacovigilance, and post-authorization safety monitoring to address residual sedation, falls, cognitive effects, complex sleep behaviors, and drug-drug interactions. Commercial and medical teams should align education with clinical guidelines, emphasizing appropriate diagnosis, patient selection, duration of therapy, tapering strategies, and integration with cognitive behavioral therapy for insomnia. Access strategies should reflect country-level reimbursement realities, affordability constraints, and the role of primary care physicians, psychiatrists, neurologists, geriatricians, pulmonologists, and pharmacists. Digital sleep tools and AI-enabled support should be deployed only where clinically validated, privacy-protective, and capable of improving adherence, monitoring, or treatment personalization. Leaders should also invest in inclusive research across older adults, women, shift workers, patients with psychiatric comorbidity, and populations historically underrepresented in sleep medicine studies.

Research Methodology

This executive summary is developed through a structured secondary research approach using verified public-domain and authoritative sources, including regulatory agency communications, clinical practice guidelines, peer-reviewed medical literature, pharmacovigilance references, public health publications, and internationally recognized healthcare policy resources. The methodology emphasizes data triangulation across clinical evidence, regulatory standards, treatment guidelines, and regional healthcare access indicators. Insights were assessed for relevance to insomnia pharmacological treatment, including medication classes, safety considerations, prescribing practices, patient populations, comorbidity patterns, and evolving digital health applications. Regional, group, and country-level narratives were synthesized to reflect documented healthcare system characteristics, regulatory maturity, demographic drivers, and treatment access dynamics without using market estimation, market sizing, market share, or forecasting. The analysis prioritizes reproducibility, source credibility, clinical validity, and consistency with current evidence-based sleep medicine practices.

Conclusion

Insomnia pharmacological treatment is entering a more selective, safety-conscious, and patient-centered phase. The sector is being shaped by the shift from broad sedative approaches toward mechanism-informed therapies, stronger integration with behavioral care, and wider use of real-world safety monitoring. Artificial intelligence and digital sleep technologies can improve screening, adherence tracking, and individualized prescribing, but their value depends on clinical validation and responsible governance. Regional differences in access, reimbursement, regulation, and clinical practice will continue to influence therapy adoption, while countries with aging populations, high stress exposure, and strong sleep medicine infrastructure are likely to remain central to innovation and evidence generation. For industry leaders, the most defensible path forward is to combine differentiated pharmacology with rigorous safety data, guideline-aligned education, equitable access planning, and measurable improvements in patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Insomnia Pharmacological Treatment Market, by Drug Class

• 7.1. Introduction
• 7.2. Benzodiazepines
  • 7.2.1. Estazolam
  • 7.2.2. Temazepam
  • 7.2.3. Triazolam
• 7.3. Melatonin Receptor Agonists
  • 7.3.1. Agomelatine
  • 7.3.2. Melatonin
  • 7.3.3. Ramelteon
• 7.4. Non Benzodiazepine Hypnotics
  • 7.4.1. Eszopiclone
  • 7.4.2. Zaleplon
  • 7.4.3. Zolpidem
    • 7.4.3.1. Extended Release
    • 7.4.3.2. Immediate Release
• 7.5. Orexin Receptor Antagonists
  • 7.5.1. Lemborexant
  • 7.5.2. Suvorexant
• 7.6. Sedating Antidepressants
  • 7.6.1. Doxepin
  • 7.6.2. Trazodone

8. Insomnia Pharmacological Treatment Market, by Dosage Form

• 8.1. Introduction
• 8.2. Capsules
  • 8.2.1. Hard Gelatin
  • 8.2.2. Soft Gelatin
• 8.3. Oral Suspension
• 8.4. Tablets
  • 8.4.1. Controlled Release
  • 8.4.2. Immediate Release

9. Insomnia Pharmacological Treatment Market, by Sleep Disorder Type

• 9.1. Introduction
• 9.2. Sleep Onset Insomnia
• 9.3. Sleep Maintenance Insomnia
• 9.4. Mixed Insomnia

10. Insomnia Pharmacological Treatment Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacy
  • 10.2.1. Private
  • 10.2.2. Public
• 10.3. Online Pharmacy
  • 10.3.1. Marketplaces
  • 10.3.2. Specialty Online Pharmacies
• 10.4. Retail Pharmacy
  • 10.4.1. Chain
  • 10.4.2. Independent

11. Insomnia Pharmacological Treatment Market, by End User

• 11.1. Introduction
• 11.2. Homecare Settings
  • 11.2.1. Assisted Living
  • 11.2.2. Private Homecare
• 11.3. Hospitals
  • 11.3.1. General Hospitals
  • 11.3.2. Psychiatric Hospitals
• 11.4. Specialty Clinics
  • 11.4.1. Outpatient Clinics
  • 11.4.2. Sleep Disorder Clinics

12. Insomnia Pharmacological Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Africa
• 12.6. Middle East

13. Insomnia Pharmacological Treatment Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Insomnia Pharmacological Treatment Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. India
• 14.5. Germany
• 14.6. United Kingdom
• 14.7. Australia
• 14.8. France
• 14.9. South Korea
• 14.10. Italy
• 14.11. Canada
• 14.12. Russia
• 14.13. Brazil
• 14.14. Mexico
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Academics Pharmaceuticals Inc
• 16.2. Alembic Pharmaceuticals Ltd
• 16.3. Alkem Laboratories Ltd
• 16.4. Astellas Pharma Inc
• 16.5. Aurobindo Pharma Ltd
• 16.6. Avadel Pharmaceuticals plc
• 16.7. Bayer AG
• 16.8. Cipla Ltd
• 16.9. Currax Pharmaceuticals LLC
• 16.10. Dr Reddy's Laboratories Ltd
• 16.11. Eisai Co Ltd
• 16.12. GlaxoSmithKline plc
• 16.13. Glenmark Pharmaceuticals Ltd
• 16.14. H Lundbeck A/S
• 16.15. Idorsia Ltd
• 16.16. Jazz Pharmaceuticals plc
• 16.17. Lupin Ltd
• 16.18. Mankind Pharma Ltd
• 16.19. Merck & Co Inc
• 16.20. Novartis AG
• 16.21. Pfizer Inc
• 16.22. Procter & Gamble Health Ltd
• 16.23. Sanofi SA
• 16.24. Sumitomo Pharma Co Ltd
• 16.25. Sun Pharmaceutical Industries Ltd
• 16.26. Takeda Pharmaceutical Company Limited
• 16.27. Teva Pharmaceutical Industries Ltd
• 16.28. Torrent Pharmaceuticals Ltd
• 16.29. Viatris Inc
• 16.30. Zydus Lifesciences Ltd